IgGenix
San Francisco
About IgGenix
IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $75.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2023)
- Website: iggenix.com
- Phone: +1 650 491 9626
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/iggenix-20385 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.